布地奈德作用及功效

(Budesonide), chemical name: 16a, 17a-22R, S-propylmethylenedioxy-pregnant-1,4-diene-11b, 21-dihydroxy-3,20-dione (16a(R), 17-(Butylidenebis(oxy))-11b, 21- dihydroxypregna-1, 4-diene-3, 20-dione), budesonide was first developed and marketed by AstraZeneca Pharmaceuticals in 1981. Budesonide is a halogen-free, topical glucocorticoid that is currently one of the most commonly used drugs for the treatment of asthma in various countries around the world. Budesonide has a strong local anti-inflammatory effect, and its mechanism may be: enhancing the stability of mast cells and lysosomal membranes, reducing degranulation and the release of lysosomal enzymes; anti-immune effects, inhibiting inflammation caused by immune responses, etc.; for patients with airway hyperresponsiveness, this product can significantly reduce the airway response to histamine and methacholine.

Clinical trials explore the clinical effectiveness of budesonide in the treatment of bronchial asthma. Methods: 92 patients with bronchial asthma admitted to our hospital from February 2013 to February 2015 were selected as the research subjects, and they were randomly divided into group A (46 cases) and group B (46 cases). Patients in group A were given conventional treatment, and patients in group B were treated with Budenofalk on the basis of conventional treatment. The clinical efficacy of the two groups of patients was then observed and compared, and the comparative results and clinical data of the two groups of patients were retrospectively analyzed.

The test results showed that the clinical efficacy of patients in group B was significantly better than that of patients in group A, and the incidence of adverse reactions in patients in group B was significantly lower than that of patients in group A. The difference was significant (P<0.05) and was statistically significant.

Conclusion: It has significant clinical effect in treating bronchial asthma with few adverse reactions and is worthy of clinical promotion and application.